EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion

Naval G Daver iD, Shahed Iqbal, Julie Huang, Camille Renard, Joyce Lin, Yang Pan, Mellissa Williamson, Giridharan Ramsingh

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Naval G Daver und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Genes, p53, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 5% to 15% of acute myeloid leukemia (AML) patients have TP53 gene mutations ( TP53 m), which are associated with very poor outcomes. Adults (≥18 years) with a new AML diagnosis were included from a nationwide, de‐identified, real‐world database. Patients receiving first‐line therapy were divided into three cohorts: venetoclax (VEN) + hypomethylating agents (HMAs; Cohort A), intensive chemotherapy (Cohort B), or HMA without VEN (Cohort C). A total of 370 newly diagnosed AML patients with TP53 m (n = 124), chromosome 17p deletion (n = 166), or both (n = 80) were included. The median age was 72 years (range, 24–84); most were male (59%) and White (69%). Baseline bone marrow (BM) blasts were ≤30%, 31%–50%, and >50% in 41%, 24%, and 29% of patients in Cohorts A, B, and C, respectively. BM remission (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genes, p53Leukemia, Myeloid, AcuteAdultAgedFemaleHumansMaleAntineoplastic Combined Chemotherapy ProtocolsChromosome DeletionChromosomesMutationProportional Hazards ModelsRetrospective StudiesTumor Suppressor Protein p53Middle AgedAged, 80 and over

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gilead Sciences, Inc., Foster City, California, USA.

ORCID-Profile: Naval G Daver

Förderung

  • Gilead Sciences

Zitieren

APA

Daver, N. G., Iqbal, S., Huang, J., Renard, C., Lin, J., Pan, Y., Williamson, M., & Ramsingh, G. (2023). Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. American Journal of Hematology. https://doi.org/10.1002/ajh.26941

Vancouver

Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, et al. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. American Journal of Hematology. 2023. doi:10.1002/ajh.26941

BibTeX
@article{Daver2023,
  author = {Daver, Naval G and Iqbal, Shahed and Huang, Julie and Renard, Camille and Lin, Joyce and Pan, Yang and Williamson, Mellissa and Ramsingh, Giridharan},
  title = {Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26941}
}
Kostenlos starten →